# Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

> **NCT02921269** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 11 (actual)

## Conditions studied

- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Recurrent Cervical Carcinoma
- Stage IV Cervical Cancer AJCC v6 and v7
- Stage IVA Cervical Cancer AJCC v6 and v7
- Stage IVB Cervical Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Atezolizumab
- **BIOLOGICAL:** Bevacizumab
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02921269
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-10
- **Primary completion:** 2020-10-01
- **Final completion:** 2021-01-13
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02921269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02921269, "Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02921269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*